Case Report June 7, 2022

Haloperidol-Induced Acute Generalized Exanthematous Pustulosis: A Rare Side Effect

; ; ; ; ;

Prim Care Companion CNS Disord 2022;24(3):21cr03051

  1. Thienvibul C, Vachiramon V, Chanprapaph K. Five-year retrospective review of acute generalized exanthematous pustulosis. Dermatol Res Pract. 2015;2015:260928. PubMed CrossRef
  2. Sidoroff A. Acute generalized exanthematous pustulosis. Chem Immunol Allergy. 2012;97:139–148. PubMed CrossRef
  3. Chang SL, Huang YH, Yang CH, et al. Clinical manifestations and characteristics of patients with acute generalized exanthematous pustulosis in Asia. Acta Derm Venereol. 2008;88(4):363–365. PubMed
  4. Sidoroff A, Dunant A, Viboud C, et al. Risk factors for acute generalized exanthematous pustulosis (AGEP): results of a multinational case-control study (EuroSCAR). Br J Dermatol. 2007;157(5):989–996. PubMed CrossRef
  5. Feldmeyer L, Heidemeyer K, Yawalkar N. Acute generalized exanthematous pustulosis: pathogenesis, genetic background, clinical variants and therapy. Int J Mol Sci. 2016;17(8):1214. PubMed CrossRef
  6. Gabay C, Towne JE. Regulation and function of interleukin-36 cytokines in homeostasis and pathological conditions. J Leukoc Biol. 2015;97(4):645–652. PubMed CrossRef
  7. Duckworth L, Maheshwari MB, Thomson MA. A diagnostic challenge: acute generalized exanthematous pustulosis or pustular psoriasis due to terbinafine. Clin Exp Dermatol. 2012;37(1):24–27. PubMed CrossRef
  8. Sidoroff A, Halevy S, Bavinck JN, et al. Acute generalized exanthematous pustulosis (AGEP): a clinical reaction pattern. J Cutan Pathol. 2001;28(3):113–119. PubMed CrossRef